Is e-signature valid for this form?

Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and UETA. For healthcare consumer records, ensure consumer disclosure and ability to withdraw consent per ESIGN; some testamentary and court filings remain exceptions.

Do I need a HIPAA addendum?

If the form contains PHI and is transmitted or stored by a third-party service, execute a Business Associate Agreement (BAA) to meet HIPAA requirements (45 CFR §164.502(e)). Document safeguards and access controls in the record.

Which fields are essential to include?

Include patient full legal name, date of birth, prescription details, dosage, prescriber name, discussion notes, signature blocks with dates, and contact information. Accurate TINs or billing identifiers may be required for pharmacy or payer interactions.

When must I retain the signed form?

Retain signed Healthcare Finasteride Disclosure Forms per HIPAA six‑year requirement (45 CFR §164.530(j)) and applicable medical record retention rules. Maintain copies for at least the active treatment period plus six years, longer if state law requires.

What if patient refuses to sign?

Document the discussion, refusal, and clinical rationale in the medical record. Consider alternative therapies and document recommended next steps. Refusal does not necessarily prevent treatment but heightens the need for thorough counseling and clear recordkeeping.

Can this be notarized or witnessed?

Notarization or witness requirements depend on state law and specific use. Routine consent forms rarely require notarization, but some states or institutional policies may request witness signatures or notarization for high-risk disclosures; confirm with state statutes or counsel.

Electronic Signature
Templates
Healthcare
Healthcare Finasteride Disclosure Form

Healthcare Finasteride Disclosure Form

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE FINASTERIDE DISCLOSURE FORM

This form documents disclosure of material information regarding the prescription of finasteride and records the patient's acknowledgment and informed consent. Finasteride is prescribed to treat androgenic alopecia (male pattern hair loss) and/or benign prostatic hyperplasia (BPH). Finasteride has specific contraindications, warnings, and potential adverse effects which are described below. The patient named below certifies that they have read, understand, and have had the opportunity to ask questions about the information provided.

Patient Information

Patient Name: Date of Birth: Gender: Address:

Phone:

Email:

Emergency Contact (Name and Relationship): Emergency Contact Phone:

Insurance Information

Insurance Provider:

Policy Number:

Group Number:

Subscriber Name:

Prescription Details

Medication: Dosage prescribed: Frequency:

Indication: Hair loss (androgenic alopecia) BPH (benign prostatic hyperplasia) Other:

Prescribing Provider: Prescription Start Date:

Medical History

Current Medications (including supplements): Allergies (drug, food, other): Prior Surgeries / Significant Medical History:

History of depression or mood disorder: Yes No

History of sexual dysfunction prior to starting finasteride: Yes No

Medication Risks, Benefits, and Alternatives

Explanation of treatment: Finasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). For androgenic alopecia finasteride may reduce hair loss and promote hair regrowth over months of therapy. For BPH it may reduce prostate size and improve urinary symptoms. Results are variable and may require months to evaluate.

Alternatives to finasteride include topical minoxidil, alternative oral therapies, procedural interventions (hair restoration surgery), watchful waiting, and management of symptoms without pharmacologic therapy. The prescriber has discussed reasonable alternatives with the patient.

Common and serious potential adverse effects include, but are not limited to:

Sexual adverse effects: decreased libido, erectile dysfunction, decreased ejaculate volume. These effects may occur during treatment and reports exist of persistence after discontinuation in some individuals.
Psychiatric effects: reports of depression and mood changes have been described.
Breast changes: tenderness, enlargement, and rarely breast lumps or gynecomastia. Any breast changes should be reported promptly.
Allergic reactions: rash, pruritus, swelling. Seek immediate care for signs of severe allergy.
Effect on laboratory tests: finasteride can lower serum PSA values; notify clinicians that you are taking finasteride when PSA testing is performed.
Fetal risk: finasteride is contraindicated in women who are or may become pregnant because of the potential risk to a male fetus. Handling crushed or broken tablets by pregnant women is contraindicated.

It is the patient's responsibility to report adverse effects promptly. If serious or life‑threatening reactions occur, seek emergency medical attention.

Acknowledgments and Specific Authorizations

I acknowledge that the prescribing provider has explained the purpose of finasteride, the expected benefits, common and serious risks, and available alternatives. I have had an opportunity to ask questions that were answered to my satisfaction.

By checking each box below I acknowledge receipt and understanding of the associated disclosure:

I understand the risk of sexual adverse effects, including possible persistence after discontinuation.
I understand the risk of mood changes and depression.
I understand finasteride is contraindicated in women who are or may become pregnant and that it may cause fetal harm.
I understand the risk of allergic reactions and will report signs of allergy immediately.
I understand the potential for breast tenderness or enlargement and will report breast changes promptly.
I understand finasteride can affect PSA test results and will inform my clinician that I take finasteride when testing is performed.

Female patients of childbearing potential: Are you currently pregnant, breastfeeding, or planning to become pregnant? Pregnant / Breastfeeding / Planning pregnancy Not pregnant / Not planning pregnancy

If female of childbearing potential: Are you currently using effective contraception? Yes No

HIPAA / Privacy Acknowledgment

I acknowledge that I have been offered or received the provider's privacy practices notice. I authorize the release of my health information as necessary for treatment, payment, and healthcare operations as permitted by law.

I acknowledge receipt of the privacy practices notice and consent to necessary disclosures for treatment and care coordination.

Authorization Expires On:

Patient Certification

I certify that I have read or had read to me the contents of this disclosure and that the risks, benefits, and alternatives have been explained. I understand that I may withdraw my consent at any time, except to the extent that action has already been taken in reliance on this consent. I understand that continuation of treatment is voluntary and that I may discontinue finasteride at my discretion after consulting my prescriber.

Patient Name:

Signature:

Date:

If signed by legal guardian or representative, indicate relationship:

What the Healthcare Finasteride Disclosure Form Is

The Healthcare Finasteride Disclosure Form is a clinical consent and information document used to explain finasteride therapy risks, benefits, and alternatives to patients considering or prescribed finasteride. It documents patient understanding, consent, and clinician disclosures about potential side effects including sexual dysfunction, mood changes, and rare but serious adverse events. The form creates a retrievable record for clinicians and institutions, supports informed decision-making, and helps satisfy regulatory and malpractice documentation standards in U.S. healthcare settings. It is commonly used in outpatient dermatology, urology, and primary care practices.

Why a Clear Disclosure Matters

A clear Healthcare Finasteride Disclosure Form protects patient autonomy, documents informed consent, and reduces clinical and legal risk by establishing that the prescriber disclosed known side effects and alternatives. It also supports compliance with HIPAA documentation and standard-of-care expectations.

Who typically completes and receives this form

Clinicians, dermatologists, urologists, primary care providers, and patients typically use or receive the Healthcare Finasteride Disclosure Form during consultation.

Prescribing clinician documents discussion of risks, benefits, alternatives, and monitoring plan.
Patient acknowledges understanding of common and rare adverse effects and asks questions.
Clinic legal or compliance teams retain signed forms for medical record and audit purposes.

Signatures indicate roles and confirm that each party received a copy for personal or medical records.

Step-by-step: completing the disclosure safely

Follow this sequence to complete the Healthcare Finasteride Disclosure Form accurately and preserve the clinical record.

01

Prepare: Gather patient history, meds, and baseline labs before prescribing.
02

Disclose: Explain potential sexual, psychological, and other risks clearly.
03

Document: Record discussion points, patient questions, and consent status.
04

Sign: Have patient and clinician sign and date the form.

Key parts of a professional disclosure form

Core components of a professional Healthcare Finasteride Disclosure Form ensure clarity, legal defensibility, and clinical follow-up instructions for safe prescribing.

Patient Info

Full demographic details, identifiers, and emergency contact information to ensure correct patient matching and reliable post-prescription communication, including phone, email, and preferred contact method for follow-up.

Clinical Risks

Clear statement of common and rare adverse effects, incidence where known, and guidance on identifying and reporting urgent symptoms such as severe mood changes or persistent sexual dysfunction.

Alternatives

List non-pharmacologic and alternative pharmacologic options, comparative risk profiles, and reasons why finasteride is recommended or not recommended for this patient based on clinical assessment.

Monitoring

Specify baseline evaluations and follow-up schedule, including recommended labs, timing for symptom checks, procedures for managing adverse events, contact for urgent concerns, and steps for medication discontinuation.

Documentation

Include clinician notes summarizing the discussion, patient questions, consent status, and any materials provided; ensure the signed form is stored in the EHR with access controls and audit logging.

Legal Notices

Provide required consumer disclosures about electronic records and withdrawal rights, and note that certain legal exceptions may preclude electronic execution and reference applicable state law where required.

Security and compliance elements to include

Encryption: TLS 1.2/1.3 in transit, AES-256 at rest

HIPAA: BAA required for third-party processors

Audit Trail: Timestamped events, IP, action log

Access Control: Role-based permissions and SSO

Authentication: Email, SMS OTP, and advanced options

Retention: Tamper-evident storage, exportable audit reports

Penalties and risks from incorrect or incomplete forms

Informed Consent Risk: Malpractice exposure if inadequate documentation

HIPAA Violation: Improper PHI handling leads to fines

State Board Action: Licensing complaints or disciplinary measures

Civil Liability: Wrongful harm claims, damages possible

Regulatory Audit: Failure to retain records invites sanctions

Patient Complaints: Reputational harm and additional scrutiny

Common preparation mistakes to avoid

Failing to document the counseling session fully, leaving only a signature without substance, undermines the record and increases legal exposure when adverse outcomes occur.
Using ambiguous language such as 'may cause issues' without quantifying likelihood or describing monitoring steps creates unclear consent and weakens defense in contested cases.
Omitting dates, mismatched patient names, or unsigned sections are common clerical errors that can invalidate consent and complicate billing or pharmacy processes.
Relying on unsecured email or unencrypted storage for signed disclosures risks HIPAA breaches and potential fines; use HIPAA-compliant systems and BAAs.

Typical e-submission workflow in clinical settings

This outlines a typical e-submission flow to collect signatures, store records, and notify care teams for the Healthcare Finasteride Disclosure Form.

Upload: Import PDF or DOCX version into e-sign platform.
Place Fields: Add signature, date, and checkbox fields.
Authenticate: Choose email, SMS code, or KBA authentication.
Archive: Store signed copy in EHR and secure archive.

Recommended eWorkflow settings

Recommended eWorkflow settings for secure and compliant online completion of the Healthcare Finasteride Disclosure Form.

Field	Configuration
Authentication	Email + SMS OTP; KBA optional for higher assurance
Audit Trail	Enable full event log with IP, timestamps, and user ID
BAA	Execute Business Associate Agreement for HIPAA-covered data
Storage	Encrypted at rest with AES-256; exportable PDF/A

Platform capabilities to look for

Choose a platform that supports secure e-signing, audit trails, HIPAA compliance with a BAA option, and flexible export to EHR systems.

Integrations: EHR, NetSuite, Salesforce supported
Formats: PDF, DOCX, and PDF/A export
Auth Methods: Email, SMS OTP, SSO options

Timing considerations and clinical checkpoints

Key timing considerations for completion, retention, and follow-up associated with this disclosure form in clinical workflows.

Form completion:

Complete and sign before initiating finasteride therapy.

Signature date:

Use MM/DD/YYYY and match medical record date.

Follow-up check:

Schedule symptom review four to twelve weeks after start.

Record retention start:

Retention period begins on date of signature.

Audit access:

Make signed copy available for audits and legal requests.

Milestones from discussion to retention

Sequential milestones from patient counseling through signing, filing, and long-term retention for the Healthcare Finasteride Disclosure Form.

01

Counseling

Provider explains risks, benefits, and alternatives

02

Decision

Patient asks questions and decides on therapy

03

Execution

Both sign, date, and store in the medical record

04

Retention

Maintain records per HIPAA and state retention rules

eSignature vendor comparison for clinical disclosure forms

Standard vendor comparison for eSignature plans relevant to clinical disclosure forms, showing starting price and key compliance features for each provider.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	Yes, 7-day trial	Varies	Varies	Varies	Varies
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Real-world examples of form use in clinics

Two examples showing how clinics integrate the Healthcare Finasteride Disclosure Form into workflows for counseling, consent, and recordkeeping.

Dermatology Clinic

A mid-size dermatology clinic updated its intake to include the Healthcare Finasteride Disclosure Form before prescription of 1 mg finasteride.

This reduced follow-up clarifications and improved documentation consistency.
Clinicians reported clearer counseling notes, faster pharmacy prior authorizations, and a single signed PDF saved in the EHR for audit responses. The clinic implemented a standard monitoring schedule documented on the form.

Urology Practice

A urology practice required the disclosure form for all new finasteride prescriptions and incorporated a follow-up workflow.

Patient-reported adverse events were tracked more consistently.
Signed records supported faster responses to patient safety questions and streamlined internal quality reviews. The practice used the form to standardize counseling language and to document monitoring intervals for each patient.

Practical tips for accurate and efficient completion

Practical tips to ensure accurate, defensible, and patient-centered completion of the Healthcare Finasteride Disclosure Form.

Use clear, nontechnical patient-facing language

Explain common and rare side effects using plain language and absolute terms when possible. Provide examples of what to monitor and give written instructions for when to seek urgent care. Confirm patient understanding verbally and in writing.

Document thoroughly and contemporaneously in chart

Record the substance of the discussion, patient questions, and any decisions in the medical record at the time of visit. Attach the signed disclosure to the visit note and ensure the EHR entry references the signed document.

Confirm patient identity and decision-making capacity

Verify identity with government ID when necessary, assess decision-making capacity, and document any limitations. If capacity is impaired, document surrogate decision-maker details and legal authority before proceeding with treatment decisions.

Secure storage and role-based access controls

Store signed disclosures in encrypted EHR fields or a secure document management system with role-based permissions. Maintain an audit trail of access and changes to defend against compliance or legal challenges.

Who can sign and what authority is required

Prescribing Clinician

Physicians, nurse practitioners, and physician assistants who prescribe finasteride should complete the disclosure with the patient, document risk discussion, and record monitoring plans and follow-up. Their signature attests to counseling provided and clinical rationale.

Patient

The patient (or legally authorized representative) reviews risks and alternatives, asks questions as needed, and signs the form to confirm informed consent. If the patient declines, the refusal and clinical implications must be documented.

Frequently asked questions and quick answers

Common questions about completion, consent, e-signing, and record retention for the Healthcare Finasteride Disclosure Form are answered below.

Need help? Contact support

Is e-signature valid for this form?
Yes. Electronic signatures are generally enforceable under the ESIGN Act (15 U.S.C. ch. 96) and UETA. For healthcare consumer records, ensure consumer disclosure and ability to withdraw consent per ESIGN; some testamentary and court filings remain exceptions.
Do I need a HIPAA addendum?
If the form contains PHI and is transmitted or stored by a third-party service, execute a Business Associate Agreement (BAA) to meet HIPAA requirements (45 CFR §164.502(e)). Document safeguards and access controls in the record.
Which fields are essential to include?
Include patient full legal name, date of birth, prescription details, dosage, prescriber name, discussion notes, signature blocks with dates, and contact information. Accurate TINs or billing identifiers may be required for pharmacy or payer interactions.
When must I retain the signed form?
Retain signed Healthcare Finasteride Disclosure Forms per HIPAA six‑year requirement (45 CFR §164.530(j)) and applicable medical record retention rules. Maintain copies for at least the active treatment period plus six years, longer if state law requires.
What if patient refuses to sign?
Document the discussion, refusal, and clinical rationale in the medical record. Consider alternative therapies and document recommended next steps. Refusal does not necessarily prevent treatment but heightens the need for thorough counseling and clear recordkeeping.
Can this be notarized or witnessed?
Notarization or witness requirements depend on state law and specific use. Routine consent forms rarely require notarization, but some states or institutional policies may request witness signatures or notarization for high-risk disclosures; confirm with state statutes or counsel.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now